Redeye updates their analysis of Idogen as company approaches clinical phase
Redeye updates their analysis of Idogen as company approaches clinical phase Idogen AB (publ) is a company that is developing tolerogenic cell therapies with the aim to treat conditions or diseases caused by an unwanted immune response in the patient. As the company now approaches clinical phase with its most advanced development program IDO 8, Redeye is intensifying their coverage of Idogen and have today published an updated analysis of Idogen AB. In summary, Redeye’s report describes Idogen as a company developing novel treatments where there are large unmedical needs. In